Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
32 studies found for:    Recurrent GBM | Immunotherapy
Show Display Options
Rank Status Study
1 Completed Vaccine Therapy in Treating Patients Undergoing Surgery for Recurrent Glioblastoma Multiforme
Condition: Recurrent Central Nervous System Neoplasm
Intervention: Biological: BTSC mRNA-loaded DCs
2 Recruiting Phase 2 Study of MEDI4736 in Patients With Glioblastoma
Condition: Glioblastoma
Interventions: Drug: MEDI4736;   Radiation: Radiotherapy;   Biological: Bevacizumab
3 Not yet recruiting A Phase I Study of Immunotherapy With GSC -Loaded Dendritic Cells in Patients With Recurrent Glioblastoma
Condition: de Novo Glioblastoma
Intervention: Biological: GSC-loaded autologous dendritic cells
4 Not yet recruiting A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent Glioblastoma Multiforme (GBM)
Conditions: Glioblastoma;   Astrocytoma, Grade IV
Intervention: Drug: EGFR(V)-EDV-Dox
5 Recruiting DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors
Condition: Glioblastoma or Gliosarcoma
Interventions: Drug: Single intratumoral injection of DNX-2401;   Drug: Interferon-gamma
6 Enrolling by invitation Proteome-based Personalized Immunotherapy of Glioblastoma
Condition: Glioblastoma
Interventions: Biological: Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes;   Biological: Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes
7 Completed Tumor Lysate Pulsed Dendritic Cell Immunotherapy for Patients With Brain Tumors
Condition: Glioblastoma
Interventions: Biological: Dendritic Cell Immunotherapy;   Biological: Dendritic Cell Vaccine
8 Active, not recruiting Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme
Conditions: Adult Brain Glioblastoma;   Glioblastoma Multiforme
Interventions: Biological: SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose);   Drug: Bevacizumab
9 Recruiting Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma
Condition: Glioblastoma
Interventions: Radiation: Stereotactic Radiosurgery;   Drug: Nivolumab;   Drug: Valproate
10 Active, not recruiting A Study of ICT-121 Dendritic Cell Vaccine in Recurrent Glioblastoma
Condition: Glioblastoma Multiforme
Intervention: Biological: ICT-121 DC vaccine
11 Completed Cellular Immunotherapy Study for Brain Cancer
Conditions: Gliomas;   Anaplastic Astrocytoma;   Anaplastic Oligodendroglioma;   Anaplastic Mixed Glioma;   Glioblastoma Multiforme;   Malignant Meningioma
Intervention: Drug: alloreactive CTL
12 Completed Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2
Conditions: Anaplastic Astrocytoma;   Anaplastic Ependymoma;   Anaplastic Meningioma;   Anaplastic Oligodendroglioma;   Brain Stem Glioma;   Ependymoblastoma;   Giant Cell Glioblastoma;   Glioblastoma;   Gliosarcoma;   Grade III Meningioma;   Meningeal Hemangiopericytoma;   Mixed Glioma;   Pineal Gland Astrocytoma;   Brain Tumor
Interventions: Biological: therapeutic allogeneic lymphocytes;   Biological: aldesleukin;   Other: laboratory biomarker analysis;   Procedure: positron emission tomography
13 Completed A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma
Condition: Glioblastoma
Interventions: Drug: Vorinostat;   Drug: Bevacizumab;   Drug: Irinotecan
14 Recruiting Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma
Conditions: Glioblastoma;   Glioblastoma Multiforme;   Glioma;   Astrocytoma;   Brain Tumor
Interventions: Biological: Dendritic cell vaccination, in addition to standard temozolomide chemotherapy and involved field radiation therapy;   Biological: Dendritic cell vaccination, with optional bevacizumab treatment for patients previously treated with bevacizumab
15 Recruiting Nivolumab With DC Vaccines for Recurrent Brain Tumors
Conditions: Malignant Glioma;   Astrocytoma;   Glioblastoma
Interventions: Drug: nivolumab;   Biological: DC
16 Terminated Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Oligodendroglioma;   Adult Diffuse Astrocytoma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Mixed Glioma;   Adult Oligodendroglioma;   Recurrent Adult Brain Tumor
Interventions: Drug: erlotinib hydrochloride;   Drug: isotretinoin;   Other: laboratory biomarker analysis;   Genetic: protein expression analysis
17 Completed Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: therapeutic autologous lymphocytes;   Genetic: gene expression analysis;   Other: laboratory biomarker analysis
18 Completed Comparison of TransMID vs Standard Treatment of Cancerous Brain Tumors
Condition: Glioblastoma
Intervention: Drug: TransMID
19 Recruiting Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
Conditions: Brain Cancer;   Brain Neoplasm;   Glioma;   Glioblastoma;   Gliosarcoma;   Malignant Brain Tumor;   Neoplasm, Neuroepithelial;   Neuroectodermal Tumors;   Neoplasm by Histologic Type;   Neoplasm, Nerve Tissue;   Nervous System Diseases
Interventions: Biological: DNX-2401;   Biological: pembrolizumab
20 Active, not recruiting Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Condition: Malignant Neoplasms of Brain
Interventions: Biological: tetanus toxoid;   Biological: therapeutic autologous dendritic cells;   Biological: therapeutic autologous lymphocytes

   Previous Page Studies Shown (1-20) Next Page (21-32) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.